Literature DB >> 10369715

Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus.

P Cresta1, L Musset, P Cacoub, L Frangeul, D Vitour, T Poynard, P Opolon, D T Nguyen, F Golliot, J C Piette, J M Huraux, F Lunel.   

Abstract

BACKGROUND: Mixed cryoglobulinaemia is closely associated with hepatitis C virus (HCV) infection. AIM: To assess in a prospective open study the efficiency of interferon alpha treatment of cryoglobulinaemia, as reflected by the disappearance of cryoglobulins and clinical manifestations of the disease, and to analyse the factors predictive of a response to interferon.
METHOD: Eighty seven consecutive patients with chronic hepatitis C treated for the first time with interferon at a dose of 3 x 10(6) international units three times a week for six months were studied. Forty three patients had cryoglobulins, which were responsible for clinical manifestations in 12.
RESULTS: At the end of interferon treatment, cryoglobulins had disappeared in 39% of the patients. A clinical improvement (except for neuropathies) was observed in all patients. Six months after interferon treatment was stopped, the same rate of response (normal alanine aminotransferase values and undectable HCV RNA) was observed in patients with or without cryoglobulins. Only 14% of patients still had undetectable cryoglobulins, and all of them also had undetectable serum HCV RNA. The disappearance of cryoglobulins was found less frequently in patients with clinical symptoms than in asymptomatic ones, but the difference was not significant. Sustained responders were more often men, infected by genotype 2 or 3, with a lower pretreatment viral load.
CONCLUSION: The presence of cryoglobulins does not seem to affect the response to interferon in HCV infected patients. The improvement in cryoglobulinaemia is strongly associated with a virological response, reinforcing the hypothesis of a direct role for HCV in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369715      PMCID: PMC1727565          DOI: 10.1136/gut.45.1.122

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

1.  Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.

Authors:  J H Hoofnagle; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; M Peters; J G Waggoner; Y Park; E A Jones
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

2.  Liver involvement in the syndrome of mixed cryoglobulinemia.

Authors:  Y Levo; P D Gorevic; H J Kassab; H Tobias; E C Franklin
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

3.  Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis.

Authors:  J C Homberg; N Abuaf; O Bernard; S Islam; F Alvarez; S H Khalil; R Poupon; F Darnis; V G Lévy; P Grippon
Journal:  Hepatology       Date:  1987 Nov-Dec       Impact factor: 17.425

4.  Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity.

Authors:  M Meltzer; E C Franklin; K Elias; R T McCluskey; N Cooper
Journal:  Am J Med       Date:  1966-06       Impact factor: 4.965

5.  Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2.

Authors:  E Martini; N Abuaf; F Cavalli; V Durand; C Johanet; J C Homberg
Journal:  Hepatology       Date:  1988 Nov-Dec       Impact factor: 17.425

6.  Biologic and clinical significance of cryoglobulins. A report of 86 cases.

Authors:  J C Brouet; J P Clauvel; F Danon; M Klein; M Seligmann
Journal:  Am J Med       Date:  1974-11       Impact factor: 4.965

7.  Treatment of idiopathic mixed cryoglobulinemia with alpha interferon.

Authors:  L Bonomo; M Casato; A Afeltra; D Caccavo
Journal:  Am J Med       Date:  1987-10       Impact factor: 4.965

8.  [Association of cryoglobulins and hepatic disease: incidence, nature and immunochemical characteristics of cryoglobulinemia].

Authors:  J P Zarski; D Rougier; H Aubert; J C Renversez; D Cordonnier; P Stoebner; M Rachail
Journal:  Gastroenterol Clin Biol       Date:  1984-11

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

Review 10.  Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.

Authors:  P D Gorevic; H J Kassab; Y Levo; R Kohn; M Meltzer; P Prose; E C Franklin
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  11 in total

1.  Association of BAFF -871C/T Promoter Polymorphism with Hepatitis C-Related Mixed Cryoglobulinemia in a Cohort of Egyptian Patients.

Authors:  Mona Wagdy Ayad; Amany A Elbanna; Dalia A Elneily; Amany S Sakr
Journal:  Mol Diagn Ther       Date:  2015-04       Impact factor: 4.074

Review 2.  Hepatitis C virus-associated extrahepatic manifestations: a review.

Authors:  Damien Sène; Nicolas Limal; Patrice Cacoub
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

3.  Treatment of hepatitis C cryoglobulinemia: mission and challenges.

Authors:  Zeid Kayali; Douglas R Labrecque; Warren N Schmidt
Journal:  Curr Treat Options Gastroenterol       Date:  2006

4.  Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia.

Authors:  Eva Zusinaite; Kaja Metskula; Riina Salupere
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

Review 5.  Hepatitis C virus-induced cryoglobulinemia.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  Kidney Int       Date:  2009-07-15       Impact factor: 10.612

6.  Rituximab in cryoglobulinemic peripheral neuropathy.

Authors:  Roberto Cavallo; Dario Roccatello; Elisa Menegatti; Carla Naretto; Franca Napoli; Simone Baldovino
Journal:  J Neurol       Date:  2009-03-05       Impact factor: 4.849

7.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

Review 8.  [Vasculitis associated with viral infections].

Authors:  Pascal Cohen; Loïc Guillevin
Journal:  Presse Med       Date:  2004-11-06       Impact factor: 1.228

9.  Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia.

Authors:  Supriya Joshi; Magdalena Kuczynski; E Jenny Heathcote
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.487

10.  Chapter 9: Infection-related glomerulonephritis.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.